Proline-rich transmembrane protein 2 regulates the magnitude and frequency of dopamine release by repetitive neuronal stimuli in the striatum of L-dopa-treated mice.
L‐dopa
Prrt2
dopamine
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
28 Aug 2024
28 Aug 2024
Historique:
revised:
11
08
2024
received:
29
06
2024
accepted:
14
08
2024
medline:
29
8
2024
pubmed:
29
8
2024
entrez:
28
8
2024
Statut:
aheadofprint
Résumé
Mutations in proline-rich transmembrane protein 2 (PRRT2) cause paroxysmal kinesigenic dyskinesia (PKD). Recently, we reported that a Prrt2 mutation exacerbated L-dopa-induced motor deficits in mice, suggesting that the basal ganglia might contribute to PKD pathology. Here, we demonstrated that the Prrt2 mutation enhanced depolarization stimuli-induced extracellular dopamine levels in the mouse striatum, which were attenuated by repeated stimulation. L-dopa administration maintained high dopamine levels in Prrt2-KI mice even during repetitive stimuli but did not affect dopamine levels in wild-type mice. Thus, the enhanced and prolonged responsiveness of dopamine release in nigrostriatal dopaminergic neurons to sequential excitation may be partially implicated in Prrt2-related dyskinesia.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP16ek0109119h
Organisme : Japan Society for the Promotion of Science
ID : 18H02720
Organisme : Japan Society for the Promotion of Science
ID : 20K22688
Organisme : Japan Society for the Promotion of Science
ID : 21H02809
Informations de copyright
© 2024 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
Références
Chen WJ, Lin Y, Xiong ZQ, Wei W, Ni W, Tan GH, et al. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet. 2011;43(12):1252–1255.
Ebrahimi‐Fakhari D, Saffari A, Westenberger A, Klein C. The evolving spectrum of PRRT2‐associated paroxysmal diseases. Brain. 2015;138(12):3476–3495.
Hatta D, Kanamoto K, Makiya S, Watanabe K, Kishino T, Kinoshita A, et al. Proline‐rich transmembrane protein 2 knock‐in mice present dopamine‐dependent motor deficits. J Biochem. 2023;174(6):561–570.
Fruscione F, Valente P, Sterlini B, Romei A, Baldassari S, Fadda M, et al. PRRT2 controls neuronal excitability by negatively modulating Na+ channel 1.2/1.6 activity. Brain. 2018;141(4):1000–1016.
Coleman J, Jouannot O, Ramakrishnan SK, Zanetti MN, Wang J, Salpietro V, et al. PRRT2 regulates synaptic fusion by directly modulating SNARE complex assembly. Cell Rep. 2018;22(3):820–831.
Tan GH, Liu YY, Wang L, Li K, Zhang ZQ, Li HF, et al. PRRT2 deficiency induces paroxysmal kinesigenic dyskinesia by regulating synaptic transmission in cerebellum. Cell Res. 2018;28(1):90–110.
Ribot B, Aupy J, Vidailhet M, Mazère J, Pisani A, Bezard E, et al. Dystonia and dopamine: from phenomenology to pathophysiology. Prog Neurobiol. 2019;182:101678.
Ikeda R, Igari Y, Fuchigami Y, Wada M, Kuroda N, Nakashima K. Pharmacodynamic interactions between MDMA and concomitants in MDMA tablets on extracellular dopamine and serotonin in the rat brain. Eur J Pharmacol. 2011;660(2–3):318–325.
Hatta D, Shirotani K, Hori Y, Kurotaki N, Iwata N. Activity‐dependent cleavage of dyskinesia‐related proline‐rich transmembrane protein 2 (PRRT2) by calpain in mouse primary cortical neurons. FASEB J. 2020;34(1):180–191.
Howe M, Ridouh I, Allegra Mascaro AL, Larios A, Azcorra M, Dombeck DA. Coordination of rapid cholinergic and dopaminergic signaling in striatum during spontaneous movement. elife. 2019;8:e44903.
Gu H, Varner EL, Groskreutz SR, Michael AC, Weber SG. In vivo monitoring of dopamine by microdialysis with 1 min temporal resolution using online capillary liquid chromatography with electrochemical detection. Anal Chem. 2015;87(12):6088–6094.
Tammimäki A, Käenmäki M, Kambur O, Kulesskaya N, Keisala T, Karvonen E, et al. Effect of S‐COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. Psychopharmacology. 2010;211(4):389–401.
Adachi K, Miwa H, Kusumoto H, Shimazu S, Kondo T. Effects of subchronic treatment with selegiline on L‐DOPA‐induced increase in extracellular dopamine level in rat striatum. J Pharmacol Sci. 2006;101(4):286–292.
Nevalainen N, Af Bjerkén S, Lundblad M, Gerhardt GA, Strömberg I. Dopamine release from serotonergic nerve fibers is reduced in L ‐DOPA‐induced dyskinesia. J Neurochem. 2011;118(1):12–23.
Halff EF, Natesan S, Bonsall DR, Veronese M, Garcia‐Hidalgo A, Kokkinou M, et al. Evaluation of intraperitoneal [18F]‐FDOPA administration for micro‐PET imaging in mice and assessment of the effect of subchronic ketamine dosing on dopamine synthesis capacity. Mol Imaging. 2022;2022:4419221.